Benedito A. Carneiro, MD, MS (@bcarneiro7) 's Twitter Profile
Benedito A. Carneiro, MD, MS

@bcarneiro7

Oncologist, Director of Clinical Research & Phase I, Lifespan Cancer Institute, Co-Leader Therapeutics Program, Legorreta Cancer Center at Brown University

ID: 874011753738383360

calendar_today11-06-2017 21:13:35

48 Tweet

266 Followers

118 Following

Wafik S. El-Deiry, MD, PhD, FACP (@weldeiry) 's Twitter Profile Photo

We continued the tradition with a wonderful reception organized by Dr. Howard Safran at American Society of Clinical Oncology (ASCO #ASCO23) for Brown University and faculty who are members of the Legorreta Cancer Center Legorreta Cancer Center at Brown University @LifespanHlthSys and Care New England. We had

We continued the tradition with a wonderful reception organized by Dr. Howard Safran at American Society of Clinical Oncology (<a href="/ASCO/">ASCO</a> #ASCO23) for <a href="/BrownUniversity/">Brown University</a> and faculty who are members of the Legorreta Cancer Center <a href="/BrownUCancer/">Legorreta Cancer Center at Brown University</a> @LifespanHlthSys and <a href="/carenewengland/">Care New England</a>. We had
Benedito A. Carneiro, MD, MS (@bcarneiro7) 's Twitter Profile Photo

Exceptional presentation by Dr Howard Safran of a first-in-class TriNKET molecule as a novel immunotherapy strategy with significant contribution from Brown University/Lifespan phase I program. Congratulations to research team and gratitude to patients driving this discovery.

Wafik S. El-Deiry, MD, PhD, FACP (@weldeiry) 's Twitter Profile Photo

We received a great deal of feedback from our #LegorretaCancerCenter EAB throughout the day as we forge ahead towards NCI standards of excellence. This is much needed in Rhode Island and takes years. Our last EAB was late 2020 and so we had much to share. shiyoko Robert W. Sobol

We received a great deal of feedback from our #LegorretaCancerCenter EAB throughout the day as we forge ahead towards NCI standards of excellence. This is much needed in Rhode Island and takes years. Our last EAB was late 2020 and so we had much to share. <a href="/ShiOnaCo/">shiyoko</a> <a href="/rwsobol/">Robert W. Sobol</a>
Sumanta K. Pal, MD, FASCO (@montypal) 's Twitter Profile Photo

Amazing to watch history being made (virtually at the moment) by Tom Powles @bartsemc. Huge congrats to the #EV302 investigators. Love Tom's comment re: the many pts who participated not just in this study but in the many preceding studies who helped us get to this point.

Amazing to watch history being made (virtually at the moment) by <a href="/tompowles1/">Tom Powles</a> @bartsemc. Huge congrats to the #EV302 investigators. Love Tom's comment re: the many pts who participated not just in this study but in the many preceding studies who helped us get to this point.
Wafik S. El-Deiry, MD, PhD, FACP (@weldeiry) 's Twitter Profile Photo

Excited to share preprint by Maximilian Pinho Schwermann #eldeirylab and collaborators Androgen receptor signaling blockade enhances NK cell-mediated killing of prostate cancer cells and sensitivity to NK cell checkpoint blockade Maximilian Pinho-Schwermann, Benedito A. Carneiro

HemOnc Today (@hemonctoday) 's Twitter Profile Photo

.Wafik S. El-Deiry, MD, PhD, FACP has been elected chair of the Worldwide Innovative Networking (WIN) in Personalized Cancer Medicine Association — WIN Consortium. El-Deiry started his term as WIN Consortium chair in December. WIN Consortium Legorreta Cancer Center at Brown University Read more 👇 bit.ly/3Od0kdJ

OncoDaily (@oncodaily) 's Twitter Profile Photo

Rhode Island has one of the highest rates of bladder cancer in the US - Wafik S. El-Deiry, MD, PhD, FACP #BladderCancer #Cancer #OncoDaily #Oncology #RhodeIsland oncodaily.com/36505.html

Wafik S. El-Deiry, MD, PhD, FACP (@weldeiry) 's Twitter Profile Photo

Today’s WIN Consortium MTB had well over 30 participants from the US, Canada, Spain, Australia and Abu Dhabi. We had world experts on molecular drivers such as MDM2, EGFR, MET, RET as well as innovative immunotherapy combinations and ADC and bispecific Ab clinical trials. There

Today’s <a href="/WIN_Consortium/">WIN Consortium</a> MTB had well over 30 participants from the US, Canada, Spain, Australia and Abu Dhabi. We had world experts on molecular drivers such as MDM2, EGFR, MET, RET as well as innovative immunotherapy combinations and ADC and bispecific Ab clinical trials. There